Intel expands the portfolio’s semiconductor engagement, while Revolution Medicines, Bayer, and Palantir shape the week’s corporate news.
The past week brought a new portfolio position as well as several company-specific developments within the UMBRELLA Strategy. Intel was newly added, thereby increasing the strategy’s engagement in semiconductor production and AI infrastructure.
Simultaneously, Revolution Medicines reported another regulatory milestone for RASONQUE™, Bayer came into focus ahead of an important Roundup hearing, and Palantir proved volatile given the shifting sentiment toward AI stocks.
Following the addition of Intel, the UMBRELLA Strategy comprises 11 stocks, representing approximately 99.4% of the portfolio. The cash ratio stands at about 0.6%.
Intel: New addition to the UMBRELLA Strategy
Intel was added to the UMBRELLA Strategy during the week with an initial weighting of around 3.2%.
The company occupies a strategically important position in efforts to expand semiconductor production in the USA and Europe. At the same time, the investment thesis depends on the successful execution of the production roadmap and the further development of Intel Foundry.
MUMAK Assessment
Intel’s strategic position is attractive. However, high investment requirements, strong competition, and execution risks remain key factors. The position therefore starts with a moderate weighting and will be monitored with regard to further operational and technical chart development.
Revolution Medicines: RASONQUE receives further FDA status
Revolution Medicines remained the largest portfolio position with a weighting of approximately 17.3%.
During the week, the company announced that the US FDA granted RASONQUE™ in combination with gemcitabine and nab-paclitaxel Breakthrough Therapy Designation for the first-line treatment of metastatic pancreatic cancer.
The status expands the regulatory potential of RASONQUE beyond its previous scope and strengthens the strategic importance of the agent within the company’s pipeline.
MUMAK Assessment
The recent FDA status supports the fundamental investment thesis for Revolution Medicines. Crucial now are further clinical data, regulatory progress, and the company’s ability to expand RASONQUE to additional treatment areas.
Bayer: Roundup uncertainty weighs on the stock
Bayer came under pressure during the week as ongoing uncertainty surrounding the Roundup litigation continued to weigh on market sentiment.
The recent US court hearing on the proposed settlement of Roundup lawsuits brought no immediate clarity. Bayer had already pointed out that a court decision is not expected until a later date. The lack of a short-term solution contributed to renewed weakness in the stock.
MUMAK Assessment
The declining price trend shows that the market continues to expect clearer progress in settling the Roundup litigation. Until a court decision or another significant legal development occurs, Bayer stock is likely to remain volatile.
Bayer continues to represent approximately 12.8% of the UMBRELLA Strategy and is under close observation.
Palantir: AI sentiment causes volatility
Palantir proved volatile during the week after sentiment toward AI companies temporarily soured.
The operational growth story of Palantir remains intact, supported by strong demand for the Artificial Intelligence Platform. At the same time, the high valuation makes the stock particularly vulnerable to changing market expectations.
MUMAK Assessment
Palantir continues to combine strong growth with increased valuation risk. The company remains a key AI position within the UMBRELLA Strategy. In the short term, however, price movements are likely to remain significant.
Semiconductor engagement increases
With Intel and Micron Technology, the UMBRELLA Strategy now holds two semiconductor positions with different strategic profiles.
Micron offers engagement in high-performance memory and the structural growth of HBM demand. Intel complements the portfolio with processor technology, advanced semiconductor manufacturing, and foundry capacities. Together, the two positions expand the portfolio’s participation in the global expansion of AI infrastructure.
Current positioning of the UMBRELLA Strategy
| Position | Weighting | Performance since purchase |
|---|---|---|
| Revolution Medicines | 17.1% | +18.8% |
| Johnson & Johnson | 14.0% | +9.6% |
| Eli Lilly | 13.5% | +4.6% |
| Bayer | 12.8% | +8.9% |
| SpaceX | 12.6% | +8.3% |
| Palantir Technologies | 8.9% | +2.6% |
| MercadoLibre | 8.5% | −5.6% |
| Intel | 3.2% | −0.4% |
| Rheinmetall | 3.1% | −16.6% |
| Micron Technology | 2.9% | −0.9% |
| TKMS | 2.7% | −5.1% |
Source: wikifolio.com, UMBRELLA (WFUMBRELLA), as of 2026-09-18.
RED HOT CHILI™ MUMAK
The RED HOT CHILI™ MUMAK was not awarded this week, as none of the analyzed companies showed a sufficiently strong alignment across all five levels of the MUMAK® methodology: geopolitics, sector, fundamentals, news flow and market sentiment, and the technical chart pattern.
RED HOT CHILI™ MUMAK of the week
Key Takeaway
The past week was shaped by the addition of Intel and several company-specific developments in the areas of healthcare, technology, and legal risks.
Intel expands the semiconductor engagement of the UMBRELLA Strategy, while the recent FDA status supports the fundamental outlook for Revolution Medicines. Bayer remains dependent on progress in the Roundup litigation. Palantir continues to reflect the high volatility surrounding AI companies.
With 11 positions, an equity ratio of 99.4%, and a cash ratio of around 0.6%, the UMBRELLA Strategy is currently almost fully invested. Further portfolio decisions depend on the alignment between fundamental developments, market sentiment, and technical chart signals.
